Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
40%
Ph phase_2
3
60%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Completed2
unknown1
Withdrawn1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 32 (40.0%)

Trials by Status

unknown120%
withdrawn120%
completed240%
suspended120%

Recent Activity

0 active trials
Showing 5 of 5
suspendedphase_3

Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes

NCT04943692
withdrawnphase_2

Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2

NCT04626089
completedphase_2

Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

NCT04625985
completedphase_3

Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes

NCT01386671
unknownphase_2

Efficacy Study of Metformin Glycinate on Postprandial Lipemia

NCT02064881

Clinical Trials (5)

Showing 5 of 5 trials
NCT04943692Phase 3

Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes

Suspended
NCT04626089Phase 2

Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2

Withdrawn
NCT04625985Phase 2

Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

Completed
NCT01386671Phase 3

Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes

Completed
NCT02064881Phase 2

Efficacy Study of Metformin Glycinate on Postprandial Lipemia

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5